Indaptus Therapeutics (NASDAQ:INDP) Trading Down 2.4%

Indaptus Therapeutics, Inc. (NASDAQ:INDP – Get Rating) fell 2.4% during trading on Wednesday . The stock traded as low as $1.61 and last traded at $1.61. 12,214 shares were traded during trading, an increase of 32% from the average session volume of 9,274 shares. The stock had previously closed at $1.65.

Indaptus Therapeutics Stock Performance

The business has a fifty day moving average of $1.69 and a two-hundred day moving average of $2.23.

Indaptus Therapeutics (NASDAQ:INDP – Get Rating) last released its quarterly earnings data on Thursday, November 10th. The company reported ($0.42) EPS for the quarter, beating the consensus estimate of ($0.47) by $0.05. Analysts anticipate that Indaptus Therapeutics, Inc. will post -1.81 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Indaptus Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. Northern Trust Corp bought a new position in Indaptus Therapeutics during the 1st quarter worth $41,000. State Street Corp acquired a new position in shares of Indaptus Therapeutics during the 1st quarter worth approximately $78,000. Renaissance Technologies LLC bought a new position in shares of Indaptus Therapeutics during the second quarter worth approximately $51,000. Strategy Asset Managers LLC acquired a new stake in shares of Indaptus Therapeutics in the third quarter valued at approximately $120,000. Finally, Vanguard Group Inc. boosted its stake in shares of Indaptus Therapeutics by 18.7% in the first quarter. Vanguard Group Inc. now owns 242,235 shares of the company’s stock valued at $969,000 after buying an additional 38,216 shares during the period. Institutional investors and hedge funds own 6.87% of the company’s stock.

About Indaptus Therapeutics

(Get Rating)

Indaptus Therapeutics, Inc is a pre-clinical biotechnology company. It engages in the development of a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. The firm created patented treatment methods and associated patented compositions for attenuation and killing of non-pathogenic, Gram-negative bacteria.